New drug being tested for MSA, ATH434 - may be useful in PD ; Phase 2 clinical trial for MSA to start by end of year

[Rhyothemis]

alteritytherapeutics.com/in...

“The publication of data demonstrating that ATH434 preserves neurons while reducing α‑synuclein in areas of pathology is exactly what we were hoping to see as we advance to clinical trials in MSA,” said Alterity Chief Executive Officer David Stamler, M.D.,. “By targeting α‑synuclein and excess brain iron in MSA, we believe that ATH434 can treat the underlying cause of this devastating disease which has no approved therapy. We remain on track to initiate our Phase 2 clinical trial of ATH434 in patients with MSA by the end of the calendar year.”

[Rhyothemis]

New review article on iron in PD:

Iron as the concert master in the pathogenic orchestra playing in sporadic Parkinson's disease

pubmed.ncbi.nlm.nih.gov/346...

wriga

[Hidden]

parkinsonsnewstoday.com/202...

[Hidden]

alteritytherapeutics.com/in...

[Rhyothemis in reply to Hidden]

Great news! { Phase 2 has been authorized in New Zealand }